A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

Major Inclusion Criteria: * Provision of written informed consent prior to any study-specific procedure; * Good health as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory measurements; * Satisfies one of the following: 1. Females not of childbearing potential: non-pregnant and non-lactating; surgically sterile or postmenopausal for 2 years or at least 1 year with a follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR 2. Males: surgically sterile, abstinent, or subject or partner is utilizing an acceptable contraceptive method during and 3 months after the last study dose; Major Exclusion Criteria: * Clinically significant disease that requires a physician's care and/or would interfere with study evaluations * Clinically significant electrocardiogram (ECG) abnormalities or laboratory results as assessed by the investigator, such as QTcF \>450; * Use of any investigational drug or participation in any investigational study within 30 days prior to screening or 5 half-lives of the study agent, whichever is longer;